The Experts below are selected from a list of 147 Experts worldwide ranked by ideXlab platform

Gerardo Gomezmoreno - One of the best experts on this subject based on the ideXlab platform.

  • evaluation of the efficacy of a topical Sialogogue spray containing malic acid 1 in elderly people with xerostomia a double blind randomized clinical trial
    Gerodontology, 2014
    Co-Authors: Gerardo Gomezmoreno, Antonio Aguilarsalvatierra, Javier Guardia, Maribel Cabreraayala, Maria Piedad Ramirezfernandez, Maximino Gonzalezjaranay, Jose Luis Calvoguirado
    Abstract:

    Objective The aim of this study was to evaluate the clinical efficacy of a topical Sialogogue spray containing 1% malic acid for elderly people affected by xerostomia. Material and methods This research took the form of a double-blind, randomized clinical trial. Forty-one individuals (mean age: 78.7 years) with xerostomia were divided into two groups: for the first ‘intervention group’ (21 subjects) a topical Sialogogue spray (1% malic acid) was applied, while for the second ‘control group’ (20 subjects), a placebo spray was applied; for both groups, the sprays were applied on demand during 2 weeks. The Xerostomia Inventory (XI) was used to evaluate xerostomia levels before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after spray application, were measured. Results XI scores decreased significantly (clinically meaningful) from 36.4 ± 7.3 points to 29.1 ± 7.1 (p < 0.05) with an XI difference of 7.2 ± 6.1, after the combination among 1% malic acid with xylitol and fluoride application. After 2 weeks of 1% malic acid application, unstimulated and stimulated salivary flows rates increased significantly (p < 0.05). Conclusion A topical Sialogogue spray containing 1% malic acid improved xerostomia in an elderly population and increased unstimulated and stimulated salivary flows rates.

  • the efficacy of a topical Sialogogue spray containing 1 malic acid in patients with antidepressant induced dry mouth a double blind randomized clinical trial
    Depression and Anxiety, 2013
    Co-Authors: Gerardo Gomezmoreno, Antonio Aguilarsalvatierra, Javier Guardia, Alejandro Uribemarioni, Maribel Cabreraayala, Rafael Arcesio Delgadoruiz, Jose Luis Calvoguirado
    Abstract:

    Background One of the most important antidepressants side effects is dry mouth. The aim of this study was to evaluate the clinical efficacy of a topical Sialogogue spray containing 1% malic acid on patients affected by dry mouth caused by antidepressants drug. Materials and methods This research took the form of a double-blind, randomized clinical trial at Faculty of Dentistry of University of Granada (Spain). Seventy participants with antidepressant-induced dry mouth were divided into two groups: for the first “intervention group” (35 subjects) a topical Sialogogue spray (1% malic acid) was applied, while for the second “control group” (35 subjects), a placebo spray was applied; for both groups, the sprays were applied on demand during 2 weeks. The Dry Mouth Questionnaire (DMQ) was used to evaluate dry mouth symptoms before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after application, were measured. Results Dry mouth symptoms improved after 1% malic acid topical spray application (p < .05). After 2 weeks of 1% malic acid application, unstimulated and stimulated salivary flows rates increased significantly (p < .05). Conclusions A Sialogogue spray containing 1% malic acid improved dry mouth feeling of the patients suffering antidepressant-induced dry mouth and increased unstimulated and stimulated salivary flows rates.

  • effectiveness of a recent topical Sialogogue in the management of drug induced xerostomia
    Journal of Clinical and Experimental Dentistry, 2011
    Co-Authors: Ma Martinpiedra, Antonio Aguilarsalvatierra, David Herrera, Gerardo Gomezmoreno
    Abstract:

    Objectives: Use of certain drugs is the most common aetiology of xerostomia. Systemic Sialogogues provide a longer effect than topic ones, but also induce relevant side effects. Topical Sialogogues, as malic acid, allow a safe use as they induce no systemic side-effects or pharmacological interactions, being especially interesting in cases of mild hyposalivation and oral dryness, mainly the chronic use of xerostomizing drugs. The aim of this study was to evaluate the clinical effect of 1% malic acid in patients affected by xerostomia due to antihypertensives or antidepressants. Study Design: 10 patients with drug-induced xerostomia were prospectively evaluated before and after using malic acid spray during three weeks. Xerostomia Inventory (XI) was used to evaluate subjective improvement. Unstimulated and stimulated salivary flow rates were determinated. Results: Severity significantly decreased, from 38.22 to 31.00 points (p = 0.011) after using the product. 77.8% of subjects did not complain about xerostomia at the end and 66.6% achieved an improvement > 6 points. Unstimulated flow rate singnificantly increased, from 0.163 to 0.226 mL/min (p = 0.021) at the third week. Conclusions: 1% malic acid spray induces some improvement in the management of mild and reversible xerostomia. Carrying out of randomized controlled trials is justified according to this study .

Jurgen Wess - One of the best experts on this subject based on the ideXlab platform.

  • cholinergic stimulation of salivary secretion studied with m1 and m3 muscarinic receptor single and double knockout mice
    Molecular Pharmacology, 2004
    Co-Authors: Dinesh Gautam, Thomas S Heard, Yinghong Cui, Georgina Miller, Lanh M Bloodworth, Jurgen Wess
    Abstract:

    Identification of the specific muscarinic acetylcholine receptor (mAChR) subtypes mediating stimulation of salivary secretion is of considerable clinical interest. Recent pharmacological and molecular genetic studies have yielded somewhat confusing and partially contradictory results regarding the involvement of individual mAChRs in this activity. In the present study, we re-examined the roles of M(1) and M(3) mAChRs in muscarinic agonist-mediated stimulation of salivary secretion by using M(1) and M(3) receptor single-knockout (KO) mice and newly generated M(1)/M(3) receptor double-KO mice. When applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly reduced secretory activity in both M(1) and M(3) receptor single-KO mice. However, when applied at higher doses, pilocarpine induced only modestly reduced (5 mg/kg, s.c.) or unchanged (15 mg/kg, s.c.) salivation responses, respectively, in M(1) and M(3) receptor single-KO mice, indicating that the presence of either M(1) or M(3) receptors is sufficient to mediate robust salivary output. Quantitative reverse transcriptase-polymerase chain reaction studies with salivary gland tissue showed that the inactivation of the M(1) or M(3) mAChR genes did not lead to significantly altered mRNA levels of the remaining mAChR subtypes. Strikingly, the sialagogue activity of pilocarpine was abolished in M(1)/M(3) receptor double-KO mice. However, salivary glands from M(1)/M(3) receptor double-KO mice remained responsive to stimulation by the beta-adrenergic receptor agonist, (S)-isoproterenol. Taken together these studies support the concept that a mixture of M(1) and M(3) receptors mediates cholinergic stimulation of salivary flow.

  • cholinergic stimulation of salivary secretion studied with m1 and m3 muscarinic receptor single and double knockout mice
    Molecular Pharmacology, 2004
    Co-Authors: Dinesh Gautam, Thomas S Heard, Georgina Miller, Lanh M Bloodworth, Jurgen Wess
    Abstract:

    Identification of the specific muscarinic acetylcholine receptor (mAChR) subtypes mediating stimulation of salivary secretion is of considerable clinical interest. Recent pharmacological and molecular genetic studies have yielded somewhat confusing and partially contradictory results regarding the involvement of individual mAChRs in this activity. In the present study, we re-examined the roles of M1 and M3 mAChRs in muscarinic agonist-mediated stimulation of salivary secretion by using M1 and M3 receptor single-knockout (KO) mice and newly generated M1/M3 receptor double-KO mice. When applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly reduced secretory activity in both M1 and M3 receptor single-KO mice. However, when applied at higher doses, pilocarpine induced only modestly reduced (5 mg/kg, s.c.) or unchanged (15 mg/kg, s.c.) salivation responses, respectively, in M1 and M3 receptor single-KO mice, indicating that the presence of either M1 or M3 receptors is sufficient to mediate robust salivary output. Quantitative reverse transcriptase-polymerase chain reaction studies with salivary gland tissue showed that the inactivation of the M1 or M3 mAChR genes did not lead to significantly altered mRNA levels of the remaining mAChR subtypes. Strikingly, the sialagogue activity of pilocarpine was abolished in M1/M3 receptor double-KO mice. However, salivary glands from M1/M3 receptor double-KO mice remained responsive to stimulation by the β-adrenergic receptor agonist, (S)-isoproterenol. Taken together these studies support the concept that a mixture of M1 and M3 receptors mediates cholinergic stimulation of salivary flow.

Jose Luis Calvoguirado - One of the best experts on this subject based on the ideXlab platform.

  • evaluation of the efficacy of a topical Sialogogue spray containing malic acid 1 in elderly people with xerostomia a double blind randomized clinical trial
    Gerodontology, 2014
    Co-Authors: Gerardo Gomezmoreno, Antonio Aguilarsalvatierra, Javier Guardia, Maribel Cabreraayala, Maria Piedad Ramirezfernandez, Maximino Gonzalezjaranay, Jose Luis Calvoguirado
    Abstract:

    Objective The aim of this study was to evaluate the clinical efficacy of a topical Sialogogue spray containing 1% malic acid for elderly people affected by xerostomia. Material and methods This research took the form of a double-blind, randomized clinical trial. Forty-one individuals (mean age: 78.7 years) with xerostomia were divided into two groups: for the first ‘intervention group’ (21 subjects) a topical Sialogogue spray (1% malic acid) was applied, while for the second ‘control group’ (20 subjects), a placebo spray was applied; for both groups, the sprays were applied on demand during 2 weeks. The Xerostomia Inventory (XI) was used to evaluate xerostomia levels before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after spray application, were measured. Results XI scores decreased significantly (clinically meaningful) from 36.4 ± 7.3 points to 29.1 ± 7.1 (p < 0.05) with an XI difference of 7.2 ± 6.1, after the combination among 1% malic acid with xylitol and fluoride application. After 2 weeks of 1% malic acid application, unstimulated and stimulated salivary flows rates increased significantly (p < 0.05). Conclusion A topical Sialogogue spray containing 1% malic acid improved xerostomia in an elderly population and increased unstimulated and stimulated salivary flows rates.

  • the efficacy of a topical Sialogogue spray containing 1 malic acid in patients with antidepressant induced dry mouth a double blind randomized clinical trial
    Depression and Anxiety, 2013
    Co-Authors: Gerardo Gomezmoreno, Antonio Aguilarsalvatierra, Javier Guardia, Alejandro Uribemarioni, Maribel Cabreraayala, Rafael Arcesio Delgadoruiz, Jose Luis Calvoguirado
    Abstract:

    Background One of the most important antidepressants side effects is dry mouth. The aim of this study was to evaluate the clinical efficacy of a topical Sialogogue spray containing 1% malic acid on patients affected by dry mouth caused by antidepressants drug. Materials and methods This research took the form of a double-blind, randomized clinical trial at Faculty of Dentistry of University of Granada (Spain). Seventy participants with antidepressant-induced dry mouth were divided into two groups: for the first “intervention group” (35 subjects) a topical Sialogogue spray (1% malic acid) was applied, while for the second “control group” (35 subjects), a placebo spray was applied; for both groups, the sprays were applied on demand during 2 weeks. The Dry Mouth Questionnaire (DMQ) was used to evaluate dry mouth symptoms before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after application, were measured. Results Dry mouth symptoms improved after 1% malic acid topical spray application (p < .05). After 2 weeks of 1% malic acid application, unstimulated and stimulated salivary flows rates increased significantly (p < .05). Conclusions A Sialogogue spray containing 1% malic acid improved dry mouth feeling of the patients suffering antidepressant-induced dry mouth and increased unstimulated and stimulated salivary flows rates.

Antonio Aguilarsalvatierra - One of the best experts on this subject based on the ideXlab platform.

  • evaluation of the efficacy of a topical Sialogogue spray containing malic acid 1 in elderly people with xerostomia a double blind randomized clinical trial
    Gerodontology, 2014
    Co-Authors: Gerardo Gomezmoreno, Antonio Aguilarsalvatierra, Javier Guardia, Maribel Cabreraayala, Maria Piedad Ramirezfernandez, Maximino Gonzalezjaranay, Jose Luis Calvoguirado
    Abstract:

    Objective The aim of this study was to evaluate the clinical efficacy of a topical Sialogogue spray containing 1% malic acid for elderly people affected by xerostomia. Material and methods This research took the form of a double-blind, randomized clinical trial. Forty-one individuals (mean age: 78.7 years) with xerostomia were divided into two groups: for the first ‘intervention group’ (21 subjects) a topical Sialogogue spray (1% malic acid) was applied, while for the second ‘control group’ (20 subjects), a placebo spray was applied; for both groups, the sprays were applied on demand during 2 weeks. The Xerostomia Inventory (XI) was used to evaluate xerostomia levels before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after spray application, were measured. Results XI scores decreased significantly (clinically meaningful) from 36.4 ± 7.3 points to 29.1 ± 7.1 (p < 0.05) with an XI difference of 7.2 ± 6.1, after the combination among 1% malic acid with xylitol and fluoride application. After 2 weeks of 1% malic acid application, unstimulated and stimulated salivary flows rates increased significantly (p < 0.05). Conclusion A topical Sialogogue spray containing 1% malic acid improved xerostomia in an elderly population and increased unstimulated and stimulated salivary flows rates.

  • the efficacy of a topical Sialogogue spray containing 1 malic acid in patients with antidepressant induced dry mouth a double blind randomized clinical trial
    Depression and Anxiety, 2013
    Co-Authors: Gerardo Gomezmoreno, Antonio Aguilarsalvatierra, Javier Guardia, Alejandro Uribemarioni, Maribel Cabreraayala, Rafael Arcesio Delgadoruiz, Jose Luis Calvoguirado
    Abstract:

    Background One of the most important antidepressants side effects is dry mouth. The aim of this study was to evaluate the clinical efficacy of a topical Sialogogue spray containing 1% malic acid on patients affected by dry mouth caused by antidepressants drug. Materials and methods This research took the form of a double-blind, randomized clinical trial at Faculty of Dentistry of University of Granada (Spain). Seventy participants with antidepressant-induced dry mouth were divided into two groups: for the first “intervention group” (35 subjects) a topical Sialogogue spray (1% malic acid) was applied, while for the second “control group” (35 subjects), a placebo spray was applied; for both groups, the sprays were applied on demand during 2 weeks. The Dry Mouth Questionnaire (DMQ) was used to evaluate dry mouth symptoms before and after product/placebo application. Unstimulated and stimulated salivary flows rates, before and after application, were measured. Results Dry mouth symptoms improved after 1% malic acid topical spray application (p < .05). After 2 weeks of 1% malic acid application, unstimulated and stimulated salivary flows rates increased significantly (p < .05). Conclusions A Sialogogue spray containing 1% malic acid improved dry mouth feeling of the patients suffering antidepressant-induced dry mouth and increased unstimulated and stimulated salivary flows rates.

  • effectiveness of a recent topical Sialogogue in the management of drug induced xerostomia
    Journal of Clinical and Experimental Dentistry, 2011
    Co-Authors: Ma Martinpiedra, Antonio Aguilarsalvatierra, David Herrera, Gerardo Gomezmoreno
    Abstract:

    Objectives: Use of certain drugs is the most common aetiology of xerostomia. Systemic Sialogogues provide a longer effect than topic ones, but also induce relevant side effects. Topical Sialogogues, as malic acid, allow a safe use as they induce no systemic side-effects or pharmacological interactions, being especially interesting in cases of mild hyposalivation and oral dryness, mainly the chronic use of xerostomizing drugs. The aim of this study was to evaluate the clinical effect of 1% malic acid in patients affected by xerostomia due to antihypertensives or antidepressants. Study Design: 10 patients with drug-induced xerostomia were prospectively evaluated before and after using malic acid spray during three weeks. Xerostomia Inventory (XI) was used to evaluate subjective improvement. Unstimulated and stimulated salivary flow rates were determinated. Results: Severity significantly decreased, from 38.22 to 31.00 points (p = 0.011) after using the product. 77.8% of subjects did not complain about xerostomia at the end and 66.6% achieved an improvement > 6 points. Unstimulated flow rate singnificantly increased, from 0.163 to 0.226 mL/min (p = 0.021) at the third week. Conclusions: 1% malic acid spray induces some improvement in the management of mild and reversible xerostomia. Carrying out of randomized controlled trials is justified according to this study .

Dinesh Gautam - One of the best experts on this subject based on the ideXlab platform.

  • cholinergic stimulation of salivary secretion studied with m1 and m3 muscarinic receptor single and double knockout mice
    Molecular Pharmacology, 2004
    Co-Authors: Dinesh Gautam, Thomas S Heard, Yinghong Cui, Georgina Miller, Lanh M Bloodworth, Jurgen Wess
    Abstract:

    Identification of the specific muscarinic acetylcholine receptor (mAChR) subtypes mediating stimulation of salivary secretion is of considerable clinical interest. Recent pharmacological and molecular genetic studies have yielded somewhat confusing and partially contradictory results regarding the involvement of individual mAChRs in this activity. In the present study, we re-examined the roles of M(1) and M(3) mAChRs in muscarinic agonist-mediated stimulation of salivary secretion by using M(1) and M(3) receptor single-knockout (KO) mice and newly generated M(1)/M(3) receptor double-KO mice. When applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly reduced secretory activity in both M(1) and M(3) receptor single-KO mice. However, when applied at higher doses, pilocarpine induced only modestly reduced (5 mg/kg, s.c.) or unchanged (15 mg/kg, s.c.) salivation responses, respectively, in M(1) and M(3) receptor single-KO mice, indicating that the presence of either M(1) or M(3) receptors is sufficient to mediate robust salivary output. Quantitative reverse transcriptase-polymerase chain reaction studies with salivary gland tissue showed that the inactivation of the M(1) or M(3) mAChR genes did not lead to significantly altered mRNA levels of the remaining mAChR subtypes. Strikingly, the sialagogue activity of pilocarpine was abolished in M(1)/M(3) receptor double-KO mice. However, salivary glands from M(1)/M(3) receptor double-KO mice remained responsive to stimulation by the beta-adrenergic receptor agonist, (S)-isoproterenol. Taken together these studies support the concept that a mixture of M(1) and M(3) receptors mediates cholinergic stimulation of salivary flow.

  • cholinergic stimulation of salivary secretion studied with m1 and m3 muscarinic receptor single and double knockout mice
    Molecular Pharmacology, 2004
    Co-Authors: Dinesh Gautam, Thomas S Heard, Georgina Miller, Lanh M Bloodworth, Jurgen Wess
    Abstract:

    Identification of the specific muscarinic acetylcholine receptor (mAChR) subtypes mediating stimulation of salivary secretion is of considerable clinical interest. Recent pharmacological and molecular genetic studies have yielded somewhat confusing and partially contradictory results regarding the involvement of individual mAChRs in this activity. In the present study, we re-examined the roles of M1 and M3 mAChRs in muscarinic agonist-mediated stimulation of salivary secretion by using M1 and M3 receptor single-knockout (KO) mice and newly generated M1/M3 receptor double-KO mice. When applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly reduced secretory activity in both M1 and M3 receptor single-KO mice. However, when applied at higher doses, pilocarpine induced only modestly reduced (5 mg/kg, s.c.) or unchanged (15 mg/kg, s.c.) salivation responses, respectively, in M1 and M3 receptor single-KO mice, indicating that the presence of either M1 or M3 receptors is sufficient to mediate robust salivary output. Quantitative reverse transcriptase-polymerase chain reaction studies with salivary gland tissue showed that the inactivation of the M1 or M3 mAChR genes did not lead to significantly altered mRNA levels of the remaining mAChR subtypes. Strikingly, the sialagogue activity of pilocarpine was abolished in M1/M3 receptor double-KO mice. However, salivary glands from M1/M3 receptor double-KO mice remained responsive to stimulation by the β-adrenergic receptor agonist, (S)-isoproterenol. Taken together these studies support the concept that a mixture of M1 and M3 receptors mediates cholinergic stimulation of salivary flow.